2. Search Result
Search Result
Results for "

HRA

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

4

Natural
Products

1

Isotope-Labeled Compounds

3

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145962A
    MRTX-EX185 formic

    		Ras Cancer
    MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRTX-EX185 formic
  • HY-156498
    RMC-7977
    2 Publications Verification

    		 Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP Cancer
    RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
    RMC-7977
  • HY-N10336
    Notoginsenoside R4

    		VEGFR STAT Akt Ras Others
    Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3 .
    Notoginsenoside R4
  • HY-100002
    ML162
    5+ Cited Publications

    		 Glutathione Peroxidase Ferroptosis Cancer
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
    ML162
  • HY-RS06354
    HRAS Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HRAS Human Pre-designed siRNA Set A contains three designed siRNAs for HRAS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HRAS Human Pre-designed siRNA Set A
    HRAS Human Pre-designed siRNA Set A
  • HY-RS06355
    Hras Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hras Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hras gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hras Mouse Pre-designed siRNA Set A
    Hras Mouse Pre-designed siRNA Set A
  • HY-RS06356
    Hras Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hras Rat Pre-designed siRNA Set A contains three designed siRNAs for Hras gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hras Rat Pre-designed siRNA Set A
    Hras Rat Pre-designed siRNA Set A
  • HY-145962
    MRTX-EX185

    		Ras Cancer
    MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRTX-EX185
  • HY-120828
    Albenatide

    CJC 1134PC

    		 GLP Receptor Metabolic Disease
    Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice .
    Albenatide
  • HY-120763
    LB42908

    		Farnesyl Transferase Cancer
    LB42908 is a potent, selective and orally active farnesyltransferase inhibitor. LB42908 inhibits farnesylation of H-Ras, K-Ras with IC50 values of 0.9 nM, 2.4 nM for H-Ras, K-Ras, respectively. LB42908 shows antiproliferative activity. LB42908 shows antitumor activity .
    LB42908
  • HY-123242
    FTI-2153

    		Farnesyl Transferase Cancer
    FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC50 of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC50, 10 nM) than Rap1A processing. Anti-cancer activity .
    FTI-2153
  • HY-15879
    LB42708

    		Farnesyl Transferase Apoptosis Inflammation/Immunology
    LB42708 is a potent, selective and orally active farnesyltransferase inhibitor. LB42708 inhibits farnesylation of H-Ras, N-Ras and K-Ras4B with IC50s of 0.8 nM, 1.2 nM and 2.0 nM, respectively .
    LB42708
  • HY-123242A
    FTI-2153 TFA

    		Farnesyl Transferase Cancer
    FTI-2153 TFA is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC50 of 1.4 nM. FTI-2153 TFA is >3000-fold more potent at blocking H-Ras (IC50, 10 nM) than Rap1A processing. Anti-cancer activity .
    FTI-2153 TFA
  • HY-125904
    4-Hydroxyretinoic acid

    		RAR/RXR Neurological Disease Inflammation/Immunology Cancer
    4-Hydroxyretinoic acid (4-HRA) is a naturally occurring retinoid derivative with diverse biological effects. 4-Hydroxyretinoic acid is formed from retinol catalyzed by cytochrome P-450 isozyme(s), and is mainly metabolized by the liver in the body. 4-Hydroxyretinoic acid also serves as the substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. 4-Hydroxyretinoic acid regulates gene expression and cell differentiation via binding to nuclear receptor RAR (Retinoic Acid Receptor), and activates RARs and RXR-alpha, to induce cancer cell apoptosis. In addition, 4-Hydroxyretinoic acid is also involved in various physiological processes such as immune regulation, neuroprotection, and anti-oxidation .
    4-Hydroxyretinoic acid
  • HY-15136
    Lonafarnib
    5+ Cited Publications

    Sch66336

    		 Farnesyl Transferase Ras Autophagy Infection Cancer
    Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
    Lonafarnib
  • HY-120271
    GGTI-297

    		Ras Cancer
    GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC50 values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras .
    GGTI-297
  • HY-15136B
    (Rac)-Lonafarnib

    Sch66336 racemate

    		 Farnesyl Transferase Infection Cancer
    (Rac)-Lonafarnib (Sch66336 racemate) is the racemate of Lonafarnib. Lonafarnib is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities .
    (Rac)-Lonafarnib
  • HY-16111
    BMS-214662

    		Farnesyl Transferase Ras Cancer
    MS-214662 是一种法尼基转移酶 (Farnesyl Transferase) 抑制剂。BMS-214662 可通过抑制 Ras 蛋白的前基团化修饰来有效阻断 Ras 蛋白在细胞膜的定位和功能，从而发挥抗肿瘤活性。BMS-214662 对 H-Ras 的 IC50 值为 1.3 nM，对 K-Ras 的 IC50 为 8.4 nM。BMS-214662 可用于与 Ras 相关的肿瘤疾病的研究 。
    BMS-214662
  • HY-113849
    MLS-573151
    1 Publications Verification

    MLS000573151

    		 Ras Inflammation/Immunology
    MLS-573151 (MLS000573151) is a selective GTPase Cdc42 inhibitor with an EC50 of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42 .
    MLS-573151
  • HY-15136R
    Lonafarnib (Standard)

    		Farnesyl Transferase Ras Autophagy Infection Cancer
    Lonafarnib (Standard) is the analytical standard of Lonafarnib. This product is intended for research and analytical applications. Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
    Lonafarnib (Standard)
  • HY-16373
    CP-609754

    LNK-754; OSI-754

    		 Farnesyl Transferase Cancer
    CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL . CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CP-609754
  • HY-16111A
    BMS-214662 hydrochloride

    		Farnesyl Transferase Ras Cancer
    BMS-214662 hydrochloride is an inhibitor of farnesyltransferase (Farnesyl Transferase). BMS-214662 hydrochloride can effectively block the localization and function of Ras proteins on the cell membrane by inhibiting the prenylation modification of Ras proteins, thereby exerting anti-tumor activity. The IC50 value of BMS-214662 hydrochloride for H-Ras is 1.3 nM, and for K-Ras it is 8.4 nM. BMS-214662 hydrochloride can be used in the research of tumor diseases related to Ras .
    BMS-214662 hydrochloride
  • HY-151263
    G4/HDAC-IN-1

    		HDAC G-quadruplex Cancer
    G4/HDAC-IN-1 (compound a6) is a G4/HDAC dual-targeting compound. G4/HDAC-IN-1 inhibits intracellular HDAC activity with an IC50 value of 1.1 μM, and induces G4 formation. G4/HDAC-IN-1 inhibits TNBC proliferation and tumor growth in TNBC xenograft model. G4/HDAC-IN-1 can be used for the research of cancer .
    G4/HDAC-IN-1
  • HY-122862
    RAS inhibitor Abd-7
    2 Publications Verification

    		 Ras Cancer
    RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V .
    RAS inhibitor Abd-7
  • HY-B0660
    Eicosapentaenoic Acid
    Maximum Cited Publications
    18 Publications Verification

    EPA; Timnodonic acid

    		 Endogenous Metabolite Histone Demethylase Neurological Disease Cancer
    Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
    Eicosapentaenoic Acid
  • HY-W011269
    Eicosapentaenoic Acid sodium

    EPA sodium; Timnodonic acid sodium

    		 Endogenous Metabolite Histone Demethylase Cardiovascular Disease Metabolic Disease Cancer
    Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation .
    Eicosapentaenoic Acid sodium
  • HY-117935
    GGTI-286 hydrochloride

    		Ras Cancer
    GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
    GGTI-286 hydrochloride
  • HY-115489
    GGTI-286

    		Ras Cancer
    GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
    GGTI-286
  • HY-B0660A
    Eicosapentaenoic acid (metformin)

    EPA (metformin); Timnodonic acid (metformin)

    		 Endogenous Metabolite Histone Demethylase Neurological Disease Cancer
    Eicosapentaenoic Acid (EPA) metformin is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic acid metformin exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). EEicosapentaenoic acid metformin activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic acid metformin can promote relaxation of vascular smooth muscle cells and vasodilation .
    Eicosapentaenoic acid (metformin)
  • HY-115489A
    GGTI-286 TFA

    		Protein Prenyltransferase Cancer
    GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
    GGTI-286 TFA
  • HY-117807
    A-176120

    		Ras Farnesyl Transferase VEGFR Cancer
    A-176120 is a selective inhibitor of farnesyl transferase (IC50=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC50=423 nM), GGTaseII (IC50=3000 nM), and SSase (IC50>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED50=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .
    A-176120
  • HY-B0660R
    Eicosapentaenoic Acid (Standard)

    		Endogenous Metabolite Histone Demethylase Neurological Disease Cancer
    Eicosapentaenoic Acid (Standard) is the analytical standard of Eicosapentaenoic Acid. This product is intended for research and analytical applications. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
    Eicosapentaenoic Acid (Standard)
  • HY-B0660S1
    Eicosapentaenoic acid 1,2,3,4,5-13C5

    EPA 1,2,3,4,5-13C, FA 20:5-13C5

    		 Isotope-Labeled Compounds Endogenous Metabolite Histone Demethylase Neurological Disease Cancer
    Eicosapentaenoic acid 1,2,3,4,5- 13C5 (EPA 1,2,3,4,5- 13C, FA 20:5- 13C5) is 13C labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
    Eicosapentaenoic acid 1,2,3,4,5-13C5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: